, Columnist
Valeant's Asset Sale Clock is Ticking
Rumored deals have made a lot of noise but netted little cash.
This article is for subscribers only.
Valeant is the asset seller that cried "wolf."
Every couple of weeks, it seems, a new Valeant Pharmaceuticals International Inc. asset is reported to be up for sale as the company seeks to pay down some of its $30 billion in debt. Earlier in the month, Takeda Pharmaceutical Co. Ltd. was said to be considering a $10 billion deal for Salix, the gut drugmaker Valeant acquired last year. On Friday, Bloomberg reported that as many as three companies are weighing $2 billion bids for Valeant's eye-surgery division.